Track topics on Twitter Track topics that are important to you
The primary objective of the study is to evaluate the safety and tolerability of Neu-P11, following the administration of multiple ascending oral doses (2, 5, 20, 50 mg or matching placebo) given nightly over 2 periods of 5 days to male and female subjects with primary insomnia. In addition, the study is aimed to determine the pharmacokinetic profile of Neu-P11 after 1 and 5 days of administration and to evaluate the hypnotic effects of Neu-P11 as well as the effects on mood and memory. The study hypothesis is that Neu-P11 is safe, tolerated and have significant sleep promoting effects.
The effects of four multiple ascending doses of orally administered Neu-P11 will be evaluated in a double- blind, placebo-controlled, crossover design. Following a screening visit, the recruited subjects will undergo an inclusion/habituation full night PSG screening recording in the sleep clinic to exclude subjects with sleep disorders. Eligible subjects will be divided into 2 cohorts of 12 subjects each. Following screening, each cohort will be randomised to receive Neu-P11 or placebo for a first period of 5 days and will be crossed over following at least 21 days to receive placebo or a higher dose of Neu-P11 for a second period of 5 days. Each cohort will receive a different dose of Neu-P11, chosen from 2, 5, 20 and 50 mg. The starting dose is 5 mg but a smaller dose (2 mg) is also included for the purpose of pharmacodynamic evaluation. Before proceeding from 5mg to the next higher dose safety will be evaluated based on adverse events, clinical and biological data. Subjects of Cohort A will be randomised to dose levels 2 and 3 (doses 5 and 20 mg). Subjects of Cohort B will be randomised to dose levels 1 and 4 (doses 2 and 50 mg).
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Neu-P11, Neu-P11 placebo
Centre hospitallier de Rouffach
Not yet recruiting
Neurim Pharmaceuticals Ltd.
Published on BioPortfolio: 2014-08-27T03:14:05-0400
Acupuncture is widely used for treatment of insomnia. The research hypothesis is that acupuncture may be more effective than sham acupuncture to treat insomnia during pregnancy. GAS is a ...
Insomnia is a common and distressing symptom for patients on hemodialysis (HD), and there is evidence for a much larger impact on the health of patients. Chronic insomnia is disrupted slee...
The purpose of this study is to investigate whether a self-help book for insomnia, with or without therapist support, can improve sleep and alleviate insomnia symptoms in individuals suffe...
Problems sleeping are common after exposure to highly threatening experiences and can occur with and without a diagnosis of posttraumatic stress disorder (PTSD). Established treatments for...
Depression with ongoing insomnia is a common clinical presentation with patients. Clinical data suggests that patients with insomnia that receive concomitant treatment with a sleep aid exp...
Insomnia is a prevalent sleep disorder that has not been well managed thus far. There are numerous medicaments for treatment of insomnia, but they have undesirable side effects that make herbal medici...
Insomnia and depression are highly comorbid and mutually exacerbate clinical trajectories and outcomes. Cognitive behavioral therapy for insomnia (CBT-I) effectively reduces both insomnia and depressi...
The prevalence of insomnia ranges from 36% to 91% in alcohol-dependent patients and may persist after alcohol withdrawal. Acamprosate has been shown to decrease insomnia in abstinent patients. Based o...
Insomnia is a common sleep disorder that is associated with a range of adverse outcomes. Patients with insomnia exhibit hyperarousal in multiple domains, including an elevated metabolic rate, but spec...
To quantify insomnia and their components in a longitudinal cohort of pregnant women and factors associated with insomnia.
An autosomal dominant disorder characterized by degeneration of the THALAMUS and progressive insomnia. It is caused by a mutation in the prion protein (PRIONS).
Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.
An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.
A hypnotic and sedative used in the treatment of INSOMNIA.
A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...